Breaking Finance News

A statement released earlier today by RBC Capital about Vertex Pharma (NASDAQ:VRTX) bumps the target price to $175.00

RBC Capital bumped up the target of Vertex Pharma (NASDAQ:VRTX) to $175.00 stating a potential upside of 0.14%.

On 7/19/2017, Barclays released a statement for Vertex Pharma (NASDAQ:VRTX) bumped up the target price from $115.00 to $180.00 that suggested an upside of 0.36%.

Boasting a price of $153.31, Vertex Pharma (NASDAQ:VRTX) traded 1.63% higher on the day. With the last stock price close up 23.07% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Vertex Pharma has recorded a 50-day average of $154.66 and a two hundred day average of $126.67. Trading volume was down over the average, with 944,452 shares of VRTX changing hands under the typical 1,861,950

Recent Performance Chart

Vertex Pharma (NASDAQ:VRTX)

Vertex Pharma has 52 week low of $71.46 and a 52 week high of $167.86 with a PE ratio of 149.75 and has a market capitalization of $0.

In addition to RBC Capital reporting its stock price target, a total of 20 brokers have issued a research note on the company. The average stock price target is $110.30 with 8 brokers rating the stock a strong buy, 10 brokers rating the stock a buy, 7 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Vertex Pharma (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.